Literature DB >> 16934409

Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

S M Fleming1, J Salcedo, C B Hutson, E Rockenstein, E Masliah, M S Levine, M-F Chesselet.   

Abstract

Overexpression of alpha-synuclein causes familial Parkinson's disease and abnormal aggregates of the protein are present in sporadic cases of the disease. We have examined the behavioral effects of direct and indirect dopaminergic agonists in transgenic mice expressing human alpha-synuclein under the Thy-1 promoter (Thy1-aSyn, alpha-synuclein overexpressor), which exhibit progressive impairments in behavioral tests sensitive to nigrostriatal dopamine dysfunction. Male Thy1-aSyn and wild-type mice received vehicle, benserazide/L-DOPA (25 mg/kg, i.p.), high (2 mg/kg, s.c.) and low doses (0.125, 0.25, 0.5 mg/kg, s.c.) of apomorphine, and amphetamine (5 mg/kg, i.p.), beginning at 3 months of age, and were tested on the challenging beam, spontaneous activity, pole test, and gait. l-DOPA had a paradoxical effect and worsened the deficits in Thy1-aSyn mice compared with controls, whereas the high dose of apomorphine only produced few deficits above those already present in Thy1-aSyn. In contrast to wild-type mice, Thy1-aSyn mice did not show amphetamine-induced stereotypies. The results indicate that chronic overexpression of alpha-synuclein led to abnormal pharmacological responses in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934409      PMCID: PMC3108485          DOI: 10.1016/j.neuroscience.2006.07.005

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  40 in total

1.  The effect of dose, novelty, and exploration on amphetamine-produced stereotyped behavior.

Authors:  R L Russell; R O Pihl
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

2.  Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats.

Authors:  T Schallert; I Q Whishaw; V D Ramirez; P Teitelbaum
Journal:  Science       Date:  1978-03-31       Impact factor: 47.728

3.  Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice.

Authors:  Linan Chen; Barbara Cagniard; Tiffany Mathews; Sara Jones; Hyun Chul Koh; Yunmin Ding; Paul M Carvey; Zaodung Ling; Un Jung Kang; Xiaoxi Zhuang
Journal:  J Biol Chem       Date:  2005-03-30       Impact factor: 5.157

4.  Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex.

Authors:  R E Heikkila; H Orlansky; C Mytilineou; G Cohen
Journal:  J Pharmacol Exp Ther       Date:  1975-07       Impact factor: 4.030

Review 5.  Stereotyped behavior.

Authors:  A Randrup; I Munkvad
Journal:  Pharmacol Ther B       Date:  1975

6.  Analysis of the difference in the behavioral effects of apomorphine in C57BL/6 and DBA/2 mice.

Authors:  J Vetulani; M Sansone; A Oliverio
Journal:  Pharmacol Biochem Behav       Date:  1982-11       Impact factor: 3.533

7.  Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Different effects of apomorphine on locomotor activity in C57BL/6 and DBA/2 mice.

Authors:  M Sansone; M Ammassari-Teule; P Renzi; A Oliverio
Journal:  Pharmacol Biochem Behav       Date:  1981-05       Impact factor: 3.533

9.  Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor.

Authors:  Daniela Marazziti; Elisabetta Golini; Silvia Mandillo; Armando Magrelli; Walter Witke; Rafaele Matteoni; Glauco P Tocchini-Valentini
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-24       Impact factor: 11.205

10.  Different effects of apomorphine on climbing behavior and locomotor activity in three strains of mice.

Authors:  S Cabib; S Puglisi-Allegra
Journal:  Pharmacol Biochem Behav       Date:  1985-10       Impact factor: 3.533

View more
  56 in total

1.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Authors:  Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2010-12-27       Impact factor: 4.314

2.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

3.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

4.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

5.  Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study.

Authors:  Amit Khairnar; Peter Latta; Eva Drazanova; Jana Ruda-Kucerova; Nikoletta Szabó; Anas Arab; Birgit Hutter-Paier; Daniel Havas; Manfred Windisch; Alexandra Sulcova; Zenon Starcuk; Irena Rektorova
Journal:  Neurotox Res       Date:  2015-07-08       Impact factor: 3.911

Review 6.  Strengths and limitations of genetic mouse models of Parkinson's disease.

Authors:  Marie-Francoise Chesselet; Sheila Fleming; Farzad Mortazavi; Bernd Meurers
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

7.  Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Authors:  Laura M Grant; Franziska Richter; Julie E Miller; Stephanie A White; Cynthia M Fox; Chunni Zhu; Marie-Francoise Chesselet; Michelle R Ciucci
Journal:  Behav Neurosci       Date:  2014-04       Impact factor: 1.912

8.  Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.

Authors:  P O Fernagut; C B Hutson; S M Fleming; N A Tetreaut; J Salcedo; E Masliah; M F Chesselet
Journal:  Synapse       Date:  2007-12       Impact factor: 2.562

9.  Betaine restores epigenetic control and supports neuronal mitochondria in the cuprizone mouse model of multiple sclerosis.

Authors:  Naveen K Singhal; Sarah Sternbach; Sheila Fleming; Kholoud Alkhayer; John Shelestak; Daniela Popescu; Alyx Weaver; Robert Clements; Brandi Wasek; Teodoro Bottiglieri; Ernest J Freeman; Jennifer McDonough
Journal:  Epigenetics       Date:  2020-03-09       Impact factor: 4.528

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.